Eurizon Capital SGR S.p.A. Takes Position in Exelixis, Inc. $EXEL

Eurizon Capital SGR S.p.A. purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 16,715 shares of the biotechnology company’s stock, valued at approximately $734,000.

Other institutional investors have also recently made changes to their positions in the company. Anchor Investment Management LLC raised its position in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares during the period. Activest Wealth Management purchased a new stake in shares of Exelixis during the 4th quarter valued at approximately $32,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 773 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of Exelixis during the 4th quarter valued at approximately $44,000. Finally, Abich Financial Wealth Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter valued at approximately $47,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Dana Aftab sold 43,451 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total value of $2,187,757.85. Following the completion of the sale, the executive vice president directly owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the sale, the chief financial officer directly owned 952,317 shares of the company’s stock, valued at $47,615,850. The trade was a 3.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 219,170 shares of company stock valued at $10,620,641. 2.60% of the stock is owned by insiders.

Exelixis Price Performance

Shares of EXEL opened at $51.60 on Thursday. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $52.96. The stock has a market cap of $12.97 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.02 and a beta of 0.41. The firm has a fifty day moving average price of $46.54 and a 200 day moving average price of $44.39.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. During the same period in the previous year, the company earned $0.55 earnings per share. Exelixis’s quarterly revenue was up 10.0% compared to the same quarter last year. As a group, equities analysts expect that Exelixis, Inc. will post 3.18 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on EXEL. Truist Financial raised Exelixis to a “strong-buy” rating in a research report on Monday, April 27th. Morgan Stanley boosted their target price on Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Tuesday, May 19th. Barclays boosted their target price on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research report on Monday, April 20th. Finally, Stifel Nicolaus boosted their target price on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $47.35.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.